title: Endometrioid epithelial ovarian cancer : 20 years of prospectively collected data from a single center.
abstract: BACKGROUND
  Clinicopathological features and outcome of women with endometrioid and serous ovarian adenocarcinoma were compared.
  
  
  METHODS
  Between 1984 and 2004, baseline and follow-up data were prospectively recorded on 1545 patients with ovarian cancer. Of these, 270 had pure endometrioid tumors; 659 had pure serous adenocarcinoma of the ovary. Response to platinum-based chemotherapy (PBC) overall survival, stage-for-stage median progression-free survival (PFS), and cause-specific median survival were compared. Independent predictors of survival were examined by using multivariate analyses.
  
  
  RESULTS
  Median age of diagnosis for patients with endometrioid tumors was younger than those with serous adenocarcinoma of the ovary (60 years vs 62 years; P = .013). They presented more often with early disease (stage I and II; 50% vs 17%; P < .001), had less ascites, and had better performance status both overall and for stage II and III disease. More endometrioid tumors were optimally debulked overall (71% vs 45%; P < .001), but there was no difference according to stage. Objective and CA125 PBC response rates were not significantly different, but median PFS was better for patients with endometrioid tumors (24 months vs 13 months; P < .0001) as was overall median survival (48 months vs 22 months; P < .0001). This relation remained for stage II and III disease and for moderately and poorly differentiated tumors. Patients with concurrent endometrioid ovarian and endometrial malignancies had a survival advantage compared with those with ovarian malignancies alone. Independent predictors of survival after PBC were histological type, debulking status, and disease stage.
  
  
  CONCLUSIONS
  Despite similar PBC response rates, endometrioid histology is associated with better survival compared with serous adenocarcinoma of the ovary, even with stage III or poorly differentiated tumors.
authors.affiliation: Department of Medical Oncology, Edinburgh Cancer Center, Western General Hospital Campus, Edinburgh, United Kingdom. drdjs@talk21.com
authors.forename: Dawn J
authors.initials: DJ
authors.lastname: Storey
authors.forename: Robert
authors.initials: R
authors.lastname: Rush
authors.forename: Moira
authors.initials: M
authors.lastname: Stewart
authors.forename: Tzyvia
authors.initials: T
authors.lastname: Rye
authors.forename: Awatif
authors.initials: A
authors.lastname: Al-Nafussi
authors.forename: Alistair R
authors.initials: AR
authors.lastname: Williams
authors.forename: John F
authors.initials: JF
authors.lastname: Smyth
authors.forename: Hani
authors.initials: H
authors.lastname: Gabra
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology*; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D009944:Organoplatinum Compounds